SCHEMBL5923375

SCHEMBL5923375

Cc1ccnc(NC(=N)Nc2cccc(OCc3ccccc3)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ PDK1 Q15118 1/20 0.47
▸ PDK2 Q15119 1/20 0.47
▸ PDK3 Q15120 1/20 0.47
▸ PDK4 Q16654 1/20 0.47
▸ SLC2A1 P11166 1/20 0.47
▸ NR1H4 Q96RI1 3/20 0.46
▸ LMNA P02545 1/20 0.46
▸ CTSV O60911 1/20 0.46
▸ CTSL P07711 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5923264 0.86 CYP1A2 (0.52) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5923357 0.86 MAPK1 (0.57) MEN1KMT2AALDH1A1MAPK1MAPT
SCHEMBL4981980 0.84 NR1H4 (0.58) CYP1A2CYP2C19MEN1KMT2AALDH1A1
SCHEMBL5923619 0.84 KMT2A (0.54) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5923022 0.83 GBA1 (0.59) MEN1KMT2AMAPK1MAPTPDK1
SCHEMBL5923526 0.81 MAPK1 (0.57) MEN1KMT2AMAPK1PDK1PDK2
SCHEMBL5923310 0.80 RAB9A (0.52) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5923453 0.80 MAPK1 (0.63) MEN1KMT2AALDH1A1MAPK1PDK1
SCHEMBL4984259 0.80 MEN1 (0.61) CYP1A2CYP2C19MEN1KMT2AALDH1A1
SCHEMBL5923267 0.79 SMN1; SMN2 (0.54) CYP1A2CYP2D6CYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-05-11 — — US claimed
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication PIGS, GUCY1A1, GUCY1B1 CYP1A2 295/4885CYP2D6 562/4885CYP2C9 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback